U.S. markets close in 6 hours 16 minutes
  • S&P 500

    4,410.74
    +60.81 (+1.40%)
     
  • Dow 30

    34,595.41
    +427.32 (+1.25%)
     
  • Nasdaq

    13,719.23
    +177.11 (+1.31%)
     
  • Russell 2000

    1,976.46
    -27.57 (-1.38%)
     
  • Crude Oil

    87.97
    +0.62 (+0.71%)
     
  • Gold

    1,802.40
    -27.30 (-1.49%)
     
  • Silver

    22.82
    -0.99 (-4.15%)
     
  • EUR/USD

    1.1163
    -0.0082 (-0.73%)
     
  • 10-Yr Bond

    1.8260
    -0.0220 (-1.19%)
     
  • GBP/USD

    1.3404
    -0.0059 (-0.44%)
     
  • USD/JPY

    115.3000
    +0.6400 (+0.56%)
     
  • BTC-USD

    36,938.42
    -1,331.27 (-3.48%)
     
  • CMC Crypto 200

    845.23
    +25.72 (+3.14%)
     
  • FTSE 100

    7,558.93
    +89.15 (+1.19%)
     
  • Nikkei 225

    26,170.30
    -841.03 (-3.11%)
     

T2 Biosystems to Report Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • TTOO

LEXINGTON, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the fourth quarter and full year 2020 after market close on Thursday, March 4, 2021. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. The call will also be available by dialing 877-407-9208 (U.S.) or 201-493-6784 (International) five to ten minutes prior to the start time.

About T2 Biosystems:
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, the T2Resistance™ Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Cauris™ Panel, and T2Lyme™ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens.

Media Contact:
Gina Kent, Vault Communications
gkent@vaultcommunications.com
610-455-2763

Investor Contact:
Philip Trip Taylor, Gilmartin Group
philip@gilmartinIR.com
415-937-5406